$NTIP
NETWORK-1 TECHNOLOGIES, INC.

2023 Q2 Form 10-Q Financial Statement

#000107261323000335 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $283.0K $537.0K
YoY Change
Cost Of Revenue $81.00K $151.0K
YoY Change
Gross Profit $202.0K $386.0K $0.00
YoY Change -100.0%
Gross Profit Margin 71.38% 71.88%
Selling, General & Admin $669.0K $1.079M $822.0K
YoY Change -11.74% 31.27% -11.33%
% of Gross Profit 331.19% 279.53%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $82.00K $83.00K $75.00K
YoY Change 7.89% 10.67% 1.35%
% of Gross Profit 40.59% 21.5%
Operating Expenses $832.0K $1.313M $897.0K
YoY Change -0.24% 46.38% -10.39%
Operating Profit -$549.0K -$776.0K -$897.0K
YoY Change -34.17% -13.49% -107.31%
Interest Expense $370.0K $674.0K -$434.0K
YoY Change -183.15% -255.3% -10950.0%
% of Operating Profit
Other Income/Expense, Net $370.0K $674.0K -$434.0K
YoY Change -183.15% -255.3%
Pretax Income -$179.0K -$102.0K -$1.331M
YoY Change -86.0% -92.34% -110.84%
Income Tax -$94.00K -$153.0K -$452.0K
% Of Pretax Income
Net Earnings -$476.0K -$623.0K -$1.312M
YoY Change -68.93% -52.52% -113.88%
Net Earnings / Revenue -168.2% -116.01%
Basic Earnings Per Share -$0.02 -$0.03 -$0.05
Diluted Earnings Per Share -$0.02 -$0.03 -$54.87K
COMMON SHARES
Basic Shares Outstanding 23.80M shares 23.82M shares 23.91M shares
Diluted Shares Outstanding 23.80M shares 23.87M shares 23.91M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.37M $46.84M $56.54M
YoY Change -11.04% -17.15% 36.98%
Cash & Equivalents $16.62M $9.919M $42.46M
Short-Term Investments $29.76M $36.92M $14.08M
Other Short-Term Assets $88.00K $119.0K $111.0K
YoY Change -63.18% 7.21% 26.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.64M $47.14M $56.65M
YoY Change -10.94% -16.79% -5.67%
LONG-TERM ASSETS
Property, Plant & Equipment $129.0K $145.0K
YoY Change -33.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $6.187M $6.578M $3.218M
YoY Change 232.1% 104.41% -27.52%
Other Assets $13.00K $13.00K $13.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $7.756M $8.245M $5.064M
YoY Change 60.68% 62.82% -15.1%
TOTAL ASSETS
Total Short-Term Assets $46.64M $47.14M $56.65M
Total Long-Term Assets $7.756M $8.245M $5.064M
Total Assets $54.39M $55.38M $61.71M
YoY Change -4.9% -10.26% -6.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $375.0K $601.0K $490.0K
YoY Change -28.84% 22.65% 34.99%
Accrued Expenses $261.0K $517.0K $569.0K
YoY Change -38.88% -9.14% -91.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $751.0K $1.233M $4.011M
YoY Change -30.01% -69.26% -48.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $60.00K $77.00K
YoY Change -53.13%
Total Long-Term Liabilities $60.00K $77.00K $0.00
YoY Change -53.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $751.0K $1.233M $4.011M
Total Long-Term Liabilities $60.00K $77.00K $0.00
Total Liabilities $1.725M $2.318M $4.113M
YoY Change 43.63% -43.64% -51.89%
SHAREHOLDERS EQUITY
Retained Earnings -$14.76M -$14.26M
YoY Change 36.38%
Common Stock $238.0K $239.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.67M $53.06M $57.60M
YoY Change
Total Liabilities & Shareholders Equity $54.39M $55.38M $61.71M
YoY Change -4.9% -10.26% -6.52%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$476.0K -$623.0K -$1.312M
YoY Change -68.93% -52.52% -113.88%
Depreciation, Depletion And Amortization $82.00K $83.00K $75.00K
YoY Change 7.89% 10.67% 1.35%
Cash From Operating Activities -$263.0K -$290.0K -$749.0K
YoY Change -93.18% -61.28% -45.53%
INVESTING ACTIVITIES
Capital Expenditures -$524.0K
YoY Change 6450.0%
Acquisitions
YoY Change
Other Investing Activities $6.985M -$1.659M $537.0K
YoY Change -154.5% -408.94% -55.47%
Cash From Investing Activities $6.985M -$1.659M $13.00K
YoY Change -154.5% -12861.54% -98.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -26.00K -$1.580M -1.302M
YoY Change -89.68% 21.35% 7.96%
NET CHANGE
Cash From Operating Activities -263.0K -$290.0K -749.0K
Cash From Investing Activities 6.985M -$1.659M 13.00K
Cash From Financing Activities -26.00K -$1.580M -1.302M
Net Change In Cash 6.696M -$3.529M -2.038M
YoY Change -139.56% 73.16% 47.36%
FREE CASH FLOW
Cash From Operating Activities -$263.0K -$290.0K -$749.0K
Capital Expenditures -$524.0K
Free Cash Flow -$225.0K
YoY Change -83.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001065078
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
usd
CY2022Q4 nssi Accrued Contingency Fees And Related Costs
AccruedContingencyFeesAndRelatedCosts
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q1 nssi Cost Of Revenues
CostOfRevenues
usd
CY2022Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
usd
CY2022Q1 nssi Amortization Of Right Of Use Asset
AmortizationOfRightOfUseAsset
usd
CY2022Q1 nssi Increase Decrease In Other Assets
IncreaseDecreaseInOtherAssets
usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
usd
CY2022Q1 us-gaap Interest Paid
InterestPaid
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q1 nssi Accrued Dividend Rights On Restricted Stock Units
AccruedDividendRightsOnRestrictedStockUnits
usd
CY2023Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
usd
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
CY2022Q1 us-gaap Lease Cost
LeaseCost
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
1-15288
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
NETWORK-1 TECHNOLOGIES, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3027591
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
65 Locust Avenue
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Third Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New Canaan
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06840
CY2023Q1 dei City Area Code
CityAreaCode
203
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
920-1055
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
NTIP
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23800010 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9919000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13448000 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
36920000 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
34991000 usd
CY2023Q1 us-gaap Prepaid Taxes
PrepaidTaxes
177000 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
177000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
119000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
348000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
47135000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
48964000 usd
CY2023Q1 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1509000 usd
CY2022Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1592000 usd
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
6578000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
7252000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
145000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
161000 usd
CY2023Q1 us-gaap Security Deposit
SecurityDeposit
13000 usd
CY2023Q1 us-gaap Other Assets
OtherAssets
8245000 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
9005000 usd
CY2023Q1 us-gaap Assets
Assets
55380000 usd
CY2022Q4 us-gaap Assets
Assets
57969000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
601000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
507000 usd
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
115000 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
115000 usd
CY2023Q1 nssi Accrued Contingency Fees And Related Costs
AccruedContingencyFeesAndRelatedCosts
96000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
139000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
317000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
203000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
587000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
79000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
79000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1233000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1605000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1008000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1161000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
77000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
94000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2318000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2860000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1312000 usd
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23811505 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23811505 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23863639 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23863639 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
239000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
239000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67099000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66939000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14262000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12055000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
53062000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
55109000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55380000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57969000 usd
CY2023Q1 us-gaap Revenues
Revenues
537000 usd
CY2022Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 nssi Cost Of Revenues
CostOfRevenues
151000 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
298000 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
250000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
781000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
572000 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
83000 usd
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
75000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1313000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
897000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-776000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-897000 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
310000 usd
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
80000 usd
CY2023Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
364000 usd
CY2022Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-514000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
674000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-434000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-102000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-1331000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-153000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-452000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-153000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-452000 usd
CY2023Q1 nssi Loss Income Before Share Of Net Losses Of Equity Method Investee
LossIncomeBeforeShareOfNetLossesOfEquityMethodInvestee
51000 usd
CY2022Q1 nssi Loss Income Before Share Of Net Losses Of Equity Method Investee
LossIncomeBeforeShareOfNetLossesOfEquityMethodInvestee
-879000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
-674000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
-433000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-623000 usd
CY2023Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
1191000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23866821 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23909115 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23866821 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23909115 shares
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.05
CY2022Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.05
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-623000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1312000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-3000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-623000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1315000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-623000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1312000 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
83000 usd
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
75000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
161000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
55000 usd
CY2023Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-674000 usd
CY2022Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-433000 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
270000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-510000 usd
CY2023Q1 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
-153000 usd
CY2022Q1 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
-452000 usd
CY2023Q1 nssi Amortization Of Right Of Use Asset
AmortizationOfRightOfUseAsset
16000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-229000 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-39000 usd
CY2023Q1 nssi Increase Decrease In Other Assets
IncreaseDecreaseInOtherAssets
13000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
94000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-17000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-471000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-128000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-290000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-749000 usd
CY2023Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-7671000 usd
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-1100000 usd
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
9330000 usd
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
563000 usd
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
524000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1659000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13000 usd
CY2022Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
1190000 usd
CY2023Q1 nssi Value Of Shares Delivered To Fund Withholding Taxes
ValueOfSharesDeliveredToFundWithholdingTaxes
83000 usd
CY2022Q1 nssi Value Of Shares Delivered To Fund Withholding Taxes
ValueOfSharesDeliveredToFundWithholdingTaxes
112000 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
306000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1580000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1302000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3529000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2038000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13448000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44497000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9919000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42459000 usd
CY2023Q1 nssi Accrued Dividend Rights On Restricted Stock Units
AccruedDividendRightsOnRestrictedStockUnits
8000 usd
CY2023Q1 us-gaap Gain Contingency Patents Found Infringed Upon Number
GainContingencyPatentsFoundInfringedUponNumber
97 integer
CY2023Q1 nssi Expired Patents
ExpiredPatents
52 integer
CY2023Q1 nssi Foreign Patents Owned By Company
ForeignPatentsOwnedByCompany
8 integer
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zJITikBlqjBf" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[1]</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z4rxIejxKpta">Use of Estimates and Assumptions</span></b></span></td></tr></table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. The significant estimates and assumptions made in the preparation of the Company’s unaudited condensed consolidated financial statements include costs related to the Company’s assertion of litigation, valuation of the Company’s patent portfolios, stock-based compensation, the recoverability of deferred tax assets and the carrying value of the Company’s equity method investments. Actual results could be materially different from those estimates, upon which the carrying values were based.</span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts recorded to reflect the Company’s share of income or losses of its equity method investee, accounted for under the equity method, are based on estimates and the unaudited results of operations of the equity method investee and may require adjustment in the future when the audit of the equity method investee is complete. The Company reports its share of the results of its equity method investee on a one quarter lag basis.</span></p>
CY2023Q1 us-gaap Revenues
Revenues
537000 usd
CY2022Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
537000 usd
CY2023Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1006000 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1006000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1008000 usd
CY2023Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1008000 usd
nssi Recognition Net Proceeds Payment Related To Mirror Worlds Patents
RecognitionNetProceedsPaymentRelatedToMirrorWorldsPatents
3127000 usd
CY2023Q1 nssi First100
First100
0.14 pure
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z79yfs7kHqek" style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[5]           <span id="xdx_86D_zqeQ1MmukcSb">Reclassifications</span></b></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based compensation in the unaudited condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2022 has been recast and reclassified to conform to the current period presentation.</span></p>
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8473000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8473000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6964000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6881000 usd
CY2023Q1 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1509000 usd
CY2022Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1592000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
83000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
75000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
214000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
120000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
120000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
120000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
118000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
817000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1509000 usd
CY2023Q1 nssi Next125 Million
Next125Million
0.15 pure
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
625000 shares
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.87
CY2023Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
70000 shares
CY2023Q1 nssi Issuance Weightedaverage Grant Date Fair Value
IssuanceWeightedaverageGrantDateFairValue
2.25
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
123750 shares
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2.48
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
571250 shares
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.79
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
571250 shares
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1171250 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23866821 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23909115 shares
CY2023Q1 nssi Weightedaverage Common Shares Outstanding Diluted
WeightedaverageCommonSharesOutstandingDiluted
23866821 shares
CY2022Q1 nssi Weightedaverage Common Shares Outstanding Diluted
WeightedaverageCommonSharesOutstandingDiluted
23909115 shares
CY2023Q1 nssi Restricted Stock Units Excluded From Computation Of Diluted Loss Per Share Because Effect Of Inclusion Would Have Been Antidilutive
RestrictedStockUnitsExcludedFromComputationOfDilutedLossPerShareBecauseEffectOfInclusionWouldHaveBeenAntidilutive
571250 shares
CY2022Q1 nssi Restricted Stock Units Excluded From Computation Of Diluted Loss Per Share Because Effect Of Inclusion Would Have Been Antidilutive
RestrictedStockUnitsExcludedFromComputationOfDilutedLossPerShareBecauseEffectOfInclusionWouldHaveBeenAntidilutive
1171250 shares
CY2022Q1 nssi Hft Patent Acqusition Cash At Closing
HftPatentAcqusitionCashAtClosing
500000 usd
CY2022Q1 nssi Obligation To Pay Hft Seller Additional Cash Based On Achieving Certain Milestones
ObligationToPayHftSellerAdditionalCashBasedOnAchievingCertainMilestones
500000 usd
CY2022Q1 nssi Contingent Common Stock Issued Upon Achieving Certain Milestones
ContingentCommonStockIssuedUponAchievingCertainMilestones
375000 usd
CY2022Q1 nssi First50 Million
First50Million
0.15 pure
CY2022Q1 nssi Greater Than50 Million
GreaterThan50Million
0.175 pure
CY2023Q1 nssi Obligated To Pay Seller Net Proceed Percentage
ObligatedToPaySellerNetProceedPercentage
0.125 pure
CY2023Q1 nssi First125 Million
First125Million
0.10 pure
CY2023Q1 nssi Over250 Million
Over250Million
0.20 pure
CY2023Q1 nssi Next100
Next100
0.05 pure
CY2023Q1 nssi Aadditional Consideration
AadditionalConsideration
250000 usd
CY2022Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.042 pure
CY2022Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P2Y
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
145000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
161000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
79000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
79000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
77000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
94000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
156000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
173000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
19000 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
19000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
59000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
78000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
26000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
163000 usd
CY2023Q1 nssi Operating Leases Imputed Interest
OperatingLeasesImputedInterest
-7000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
156000 usd
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
680000 usd
CY2023Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
537000 usd
CY2022Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3466000 usd
CY2021Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3367000 usd
CY2022Q4 nssi Comprehensive Loss
ComprehensiveLoss
9911000 usd
CY2021Q4 nssi Comprehensive Loss
ComprehensiveLoss
4560000 usd
CY2021Q2 nssi Stock Repurchase Program Dollar Amount That May Be Repurchased
StockRepurchaseProgramDollarAmountThatMayBeRepurchased
5000000 usd
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
9349449 shares
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
18060296 usd
nssi Weighted Average Price Per Share Common Stock Subject To Repurchase
WeightedAveragePricePerShareCommonStockSubjectToRepurchase
1.93
CY2023Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
136785 shares
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
302202 usd
CY2023Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
2.21
CY2023Q1 nssi Value Of Remaining Shares That May Be Repurchased
ValueOfRemainingSharesThatMayBeRepurchased
3095688 usd
CY2022Q3 nssi Excise Tax Description
ExciseTaxDescription
The excise tax applies in case where the total value of the stock repurchase during the taxable year exceeds $1,000,000.
CY2023Q1 nssi Fdic Insured Amount
FdicInsuredAmount
250000 usd
CY2023Q1 nssi Dividends Per Share
DividendsPerShare
0.05
CY2023Q1 nssi Dividends Per Share Annual
DividendsPerShareAnnual
0.10

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
network1_10q-033123_htm.xml Edgar Link completed
0001072613-23-000335-index-headers.html Edgar Link pending
0001072613-23-000335-index.html Edgar Link pending
0001072613-23-000335.txt Edgar Link pending
0001072613-23-000335-xbrl.zip Edgar Link pending
exh31-1_18721.htm Edgar Link pending
exh31-2_18721.htm Edgar Link pending
exh32-1_18721.htm Edgar Link pending
exh32-2_18721.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
network1_10q-033123.htm Edgar Link pending
nssi-20230331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
nssi-20230331_cal.xml Edgar Link unprocessable
nssi-20230331_def.xml Edgar Link unprocessable
nssi-20230331_lab.xml Edgar Link unprocessable
nssi-20230331_pre.xml Edgar Link unprocessable
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending